Beam Therapeutics Inc. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Beam Therapeutics ended Q3 2026 with $1.043B in cash (down from $1.245B at year-end 2025) and expects cash to support operations into mid-2029 with $200M additional facility draw from Sixth Street. Key milestones: BEAM-302 (AATD) pivotal cohort dosing completion expected H1 2027; risto-cel (SCD) BLA submission expected year-end 2026; BEAM-304 (PKU) Phase 1/2 dosing initiation expected early 2027; BEAM-301 (GSDIa) initial data showed clinical proof-of-concept. Q3 net loss was $134.4M ($1.28/share) versus $112.6M ($1.10/share) in Q3 2025; R&D expenses $110.1M, G&A $31.5M. Eric Foster appointed chief commercial officer.
Why this rating
Multiple clinical programs on track toward near-term regulatory milestones (BLA submission, pivotal cohort completion, IND initiation) and 2.7-year cash runway reduce near-term funding risk. Cash burn ~$200M/quarter sustainable. However, early-stage pipeline, no approved products, and clinical execution risk temper impact relative to $1.7B market cap.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.